Armata Pharmaceuticals (NYSEAMERICAN:ARMP) Releases Quarterly Earnings Results, Beats Estimates By $0.33 EPS

Posted by Casey Walker on Nov 12th, 2026

Armata Pharmaceuticals (NYSEAMERICAN:ARMP – Get Free Report) issued its quarterly earnings data on Thursday. The company reported ($0.24) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.57) by $0.33, FiscalAI reports. Armata Pharmaceuticals had a negative return on equity of 12.24% and a negative net margin of 3,467.04%. The firm had revenue of $3.17 million during the quarter, compared to the consensus estimate of $0.45 million.

Armata Pharmaceuticals Price Performance

NYSEAMERICAN:ARMP traded down $0.17 during mid-day trading on Thursday, reaching $3.72. The company’s stock had a trading volume of 105,066 shares, compared to its average volume of 119,290. The stock has a market cap of $138.31 million, a P/E ratio of -0.49 and a beta of 1.54. Armata Pharmaceuticals has a twelve month low of $2.74 and a twelve month high of $14.98. The company’s fifty day simple moving average is $3.87 and its two-hundred day simple moving average is $6.87.

Analyst Ratings Changes

Separately, HC Wainwright reiterated a “buy” rating and set a $15.00 target price on shares of Armata Pharmaceuticals in a report on Tuesday, September 22nd. Two investment analysts have rated the stock with a Buy rating and one has issued a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $15.00.

Read Our Latest Research Report on Armata Pharmaceuticals

Armata Pharmaceuticals Company Profile

(Get Free Report)

Armata Pharmaceuticals, Inc. is a clinical-stage biotechnology company focused on developing targeted bacteriophage therapies for drug-resistant bacterial infections. Bacteriophages, or phages, are viruses that selectively infect and destroy specific bacteria, offering a potential alternative or complement to conventional antibiotics. The company’s pipeline has included inhaled and intravenously administered phage candidates designed to treat serious infections caused by pathogens such as Pseudomonas aeruginosa and Staphylococcus aureus .